FDA Brief

Warning letters Drugs

FDA warning letter to

Ava Inc.

High riskIssued Apr 14Posted May 5Center for Drug Evaluation and Research (CDER)

FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

What happened

FDA inspected Ava Inc.'s drug manufacturing facility in Willowbrook, Illinois, from October 6 to October 21, 2025. Investigators found shared HPLC usernames and passwords, analyst administrator privileges, deleted GC sequences, FTIR audit-trail gaps, and trial injections where favorable results were reported while out-of-specification results were not investigated. FDA also found the quality unit did not adequately oversee testing and release.

What FDA found

  1. Ava did not adequately control its laboratory computer systems: staff shared an HPLC username and password, analysts had administrator rights, and GC sequences were deleted.

    21 CFR 211.68(b)
  2. Laboratory records did not include complete data from all tests; trial injections and less favorable or out-of-specification results were omitted.

    21 CFR 211.194(a)
  3. The quality unit lacked the authority and oversight to approve or reject materials and products and did not investigate out-of-specification results.

    21 CFR 211.22(a); 211.160(a),(b); 211.192
  4. API testing data were incomplete because trial-injection chromatograms were not saved or kept in official batch records.

  5. Written procedures allowed trial injections that were not processed as raw data, conflicting with CGMP recordkeeping requirements.

    21 CFR 211.160(b)

What FDA wants

FDA tells Ava to correct the violations promptly and provide comprehensive assessments, CAPA plans, independent data-integrity and OOS reviews, and a qualified consultant's help; the letter does not state a specific response deadline.

Who should pay attention

  • drug companies using Ava as a contract manufacturer
  • brands selling finished drugs or APIs tested at this site
  • quality teams managing laboratory data integrity and OOS investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk